Biopharma Quarterly Dealmaking Statistics, Q4 2015
A look at financing, M&A, and alliance activity October-December 2015
Executive Summary
Biopharma financing for Q4 totaled $13.1 billion, a 35% increase over Q3, and again was dominated by follow-on public offerings. M&A reached a record $201 billion, topped by Pfizer's $160 billion buy of Allergan. Sanofi's $4.2 billion diabetes collaboration with Hanmi led the alliances.